为了评估化疗期间的运动和静坐时间是否与化疗副作用、计划化疗的完成和生存相关。我们使用了卵巢癌预后和生活方式 (OPAL) 研究的数据，该研究是一项针对新诊断上皮细胞癌成人的全国性前瞻性队列卵巢癌。在每三个月一次的问卷调查中，我们询问了过去一周的锻炼和静坐时间，以及与治疗相关的副作用。有关治疗、毒性、进展和死亡的详细信息是从病历中提取的。我们分别使用线性、Logistic 和 Cox 回归来评估运动和静坐时间、化疗副作用和完成（相对剂量强度≥85%）和生存之间的关联。 503 名符合条件的参与者被纳入一项或多项分析。参与较高强度运动（每周≥30分钟中等强度运动；24%）的患者报告慢性病/癌症治疗功能评估 (FACIT)-疲劳（32.2 vs. 26.7）和 FACT-试验结果指数显着改善(69.4 vs. 61.7) 分数，并且与最少锻炼者 (<每周 30 分钟中等强度运动

To evaluate if exercise and sitting time during chemotherapy were associated with chemotherapy side-effects, completion of planned chemotherapy and survival.We used data from the Ovarian cancer Prognosis And Lifestyle (OPAL) Study, a national prospective cohort of adults with newly-diagnosed epithelial ovarian cancer. At 3-monthly questionnaires we asked about exercise and sitting time in the past week, and treatment-related side-effects. Details about treatment, toxicities, progression and death were abstracted from medical records. We used linear, logistic and Cox regression, respectively, to assess associations between both exercise and sitting time, and chemotherapy side-effects and completion (≥85% relative dose intensity) and survival.503 eligible participants were included in one or more analyses. Patients participating in higher-intensity exercise (≥30 min of moderate-vigorous exercise/week; 24%) reported significantly better Functional Assessment of Chronic Illness/Cancer Therapy (FACIT)-Fatigue (32.2 vs. 26.7) and FACT-Trial Outcome Index (69.4 vs. 61.7) scores, and were less likely to have clinician-reported moderate-severe neurotoxicity (odds ratio [OR]:0.50; 95% confidence interval [95%CI]:0.29-0.88), than minimal exercisers (<30 min moderate-vigorous exercise/week & <120 min walking/week; 52%). Participating in higher-intensity exercise was also possibly associated with greater chemotherapy completion (OR:1.70; 95%CI:0.90-3.20), particularly for paclitaxel. Sitting time was not associated with chemotherapy completion. For patients with advanced disease who underwent cytoreduction and received first-line carboplatin and paclitaxel, there was a suggestion higher-intensity exercise during chemotherapy may improve survival (HR:0.68; 95%CI:0.47-1.01).Patients with ovarian cancer who carry out moderate-vigorous exercise during chemotherapy have fewer side-effects and potentially better completion of planned chemotherapy and overall survival.Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.